A TGF-β receptor 1 inhibitor for prevention of proliferative vitreoretinopathy

Khaled Nassar*, Swaantje Grisanti, Aysegul Tura, Julia Lüke, Matthias Lüke, Mahmoud Soliman, Salvatore Grisanti

*Corresponding author for this work
9 Citations (Scopus)

Abstract

This study evaluates the use of the TGF-β receptor 1 inhibitor LY-364947 (LY) to prevent proliferative vitreoretinopathy (PVR). For the invitro experiments Human Tenon's Fibroblasts (HTFs) and retinal pigment epithelial (RPE) cells were treated with different concentrations of LY to determine HTF proliferation and RPE transdifferentiation. For invivo testing 30 rabbits underwent a PVR trauma model. The animals received different concentrations of intravitreally injected LY, with or without vitrectomy. LY treatment reduced HTF proliferation and RPE transdifferentiation invitro. Invivo intravitreal injection of LY prevented PVR development significantly. This positive effect was also present when LY injection was combined with vitrectomy. Intravitreal injection of LY prevented tractional retinal detachment in 14 out of 15 animals. In conclusion, treatment with the TGF-β receptor 1 inhibitor LY reduces HTF proliferation and RPE transdifferentiation invitro and prevents proliferative vitreoretinopathy and subsequent tractional retinal detachment in vivo.

Original languageEnglish
JournalExperimental Eye Research
Volume123
Pages (from-to)72-86
Number of pages15
ISSN0014-4835
DOIs
Publication statusPublished - 01.01.2014

Fingerprint

Dive into the research topics of 'A TGF-β receptor 1 inhibitor for prevention of proliferative vitreoretinopathy'. Together they form a unique fingerprint.

Cite this